Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib (SuAx)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03592199
Recruitment Status : Active, not recruiting
First Posted : July 19, 2018
Last Update Posted : September 4, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Instituto do Cancer do Estado de São Paulo

Brief Summary:
This is a prospective single arm phase II study to evaluate potential prognostic and/or predictive biomarkers in patients with metastatic ccRCC undergoing treatment with 1st line sunitinib on a 4/2 schedule followed by axitinib on 2nd line therapy.

Condition or disease Intervention/treatment Phase
Clear Cell Renal Cell Carcinoma Drug: Sunitinib Phase 2

Detailed Description:
In this study, all included patients will receive sunitinib until disease progression and/or limiting toxicity. If patients develop toxicities ≥ Grade 2 on 50 mg per day 4 weeks-on / 2 weeks-off schedule, a modified schedule of 50 mg/day 2 weeks-on / 1 week-off will be offered. After disease progression on sunitinib, all eligible patients will receive axitinib 5 mg twice a day. The investigators plan to assess, by next generation sequencing, the prevalence of mutations in several cancer related genes in baseline archived tissue from the patients included in the study, and the potential correlations between these somatic mutations and anti-VEGF (Vascular Endothelial Growth Factor) therapy efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Biomarker Study of Patients With Metastatic Clear Cell Renal Carcinoma (ccRCC) Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
Actual Study Start Date : December 11, 2017
Estimated Primary Completion Date : December 11, 2019
Estimated Study Completion Date : December 11, 2022


Arm Intervention/treatment
Experimental: 1st Line Sunitinib and 2nd Line Axitinib
1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
Drug: Sunitinib
1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
Other Name: Axitinib




Primary Outcome Measures :
  1. 1st line Response Rate (RR) with Sunitinib in patients with VEGF pathway mutation [ Time Frame: through study completion (up to 2 years) ]
    First Line Response Rate (RR) With Sunitinib (RECIST 1.1) in patients with VEGF pathway mutation


Secondary Outcome Measures :
  1. 1sr line RR with Sunitinib [ Time Frame: through study completion (up to 2 years) ]
    First Line Response Rate (RR) with Sunitinib (RECIST 1.1)

  2. 2nd Line RR with Axitinib [ Time Frame: through study completion (up to 2 years) ]
    Second Line Response Rate (RR) with Axitinib (RECIST 1.1)

  3. 1st line PFS with Sunitinib [ Time Frame: through study completion (up to 2 years) ]
    First Line Progression Free Survival (PFS) with Sunitinib

  4. 2nd PFS with Axitinib [ Time Frame: through study completion (up to 2 years) ]
    Second Line Progression Free Survival (PFS) with Axitinib

  5. Overall Survival (OS) [ Time Frame: through study completion (up to 2 years) ]
    Overall Survival

  6. Incidence of Treatment-Emergent Adverse Events [ Time Frame: through study completion (up to 2 years) ]
    CTCAE v.4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Locally advanced (defined as disease not amenable to curative surgery or radiation therapy) or metastatic RCC (equivalent to Stage IV RCC according to American Joint Committee on Cancer staging) renal cell carcinoma;
  • Histologic confirmed clear cell renal cell carcinoma;
  • No prior systemic therapy (interleukin-2, interferon-α, chemotherapy, bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, everolimus or temsirolimus) for advanced or metastatic RCC;
  • Measurable disease by RECIST;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;
  • Adequate organ system functions;
  • Patients must understand and be willing to sign the written informed consent form of this study.

Exclusion Criteria:

  • Non-clear cell renal cell carcinoma
  • Pregnant or lactating female.
  • History of another malignancy. Note: Subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin carcinoma or successfully treated in situ carcinoma are eligible.
  • History or clinical evidence of central nervous system (CNS) metastases. Note: Subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery) and meet all 3 of the following criteria are eligible:

    1. Are asymptomatic
    2. No evidence of active CNS metastases for ≥3 months prior to enrolment
    3. Have no requirement for steroids or anticonvulsants
  • Clinically significant gastrointestinal abnormalities including, but not limited to:

    1. Malabsorption syndrome
    2. Major resection of the stomach or small bowel that could affect the absorption of study drug
    3. Active peptic ulcer disease
    4. Inflammatory bowel disease
    5. Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
    6. History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days prior to beginning study treatment.
  • History of any one or more of the following cardiovascular conditions within the past 12 months:

    1. Cardiac angioplasty or stenting
    2. Myocardial infarction
    3. Unstable angina
    4. Symptomatic peripheral vascular disease
    5. Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
    6. History of cerebrovascular accident including transient ischemic attack (TIA).
    7. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥150 millimeters of mercury (mmHg) or diastolic blood pressure (DBP) of ≥ 90 mmHg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03592199


Locations
Layout table for location information
Brazil
Instituto do Cancer do Estado de São Paulo
São Paulo, Brazil, 01246000
Sponsors and Collaborators
Instituto do Cancer do Estado de São Paulo
Pfizer

Layout table for additonal information
Responsible Party: Instituto do Cancer do Estado de São Paulo
ClinicalTrials.gov Identifier: NCT03592199     History of Changes
Other Study ID Numbers: NP 1096/17
First Posted: July 19, 2018    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Instituto do Cancer do Estado de São Paulo:
biomarker
metastatic
sunitinib
axitinib
next generation sequencing
clear cell renal cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Protein Kinase Inhibitors
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Sunitinib
Axitinib
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action